Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: TheStreet.com Ratings
$10.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Redhill Biopharma Ltd provides update on PK program in support of ongoing RHB-104 Phase III Crohn's Study


Monday, 6 Jan 2014 08:04am EST 

Redhill Biopharma Ltd:Reports preliminary positive results from a Phase I study with RHB-104, a combination antibiotic oral capsule formulation for the treatment of Crohn's disease, currently undergoing a Phase III study in the U.S., with additional clinical sites planned in Canada and Israel (the MAP US study).Says the single dose two-way crossover comparative Phase I study included 84 healthy male and female subjects ages 18-45 and was designed to evaluate the effect of co-administration of food on the pharmacokinetics of the constituent components of RHB-104 and two metabolites.Says the secondary objective of this study was to assess the safety and tolerability of RHB-104 under fed and fasting conditions. 

Company Quote

329.2
18.3 +5.89%
23 Nov 2014